AU2016397046B2 - Dosage regimen for the treatment of acute exacerbations of inflammatory conditions - Google Patents

Dosage regimen for the treatment of acute exacerbations of inflammatory conditions Download PDF

Info

Publication number
AU2016397046B2
AU2016397046B2 AU2016397046A AU2016397046A AU2016397046B2 AU 2016397046 B2 AU2016397046 B2 AU 2016397046B2 AU 2016397046 A AU2016397046 A AU 2016397046A AU 2016397046 A AU2016397046 A AU 2016397046A AU 2016397046 B2 AU2016397046 B2 AU 2016397046B2
Authority
AU
Australia
Prior art keywords
days
methylbenzamide
cyclopropyl
pyrazol
cyanobenzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016397046A
Other languages
English (en)
Other versions
AU2016397046A1 (en
Inventor
Cyril Clarke
Stefan De Buck
Colm Farrell
Colin ORFORD
Jacqueline PARKIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mereo Biopharma 1 Ltd
Original Assignee
Mereo Biopharma 1 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Ltd filed Critical Mereo Biopharma 1 Ltd
Publication of AU2016397046A1 publication Critical patent/AU2016397046A1/en
Application granted granted Critical
Publication of AU2016397046B2 publication Critical patent/AU2016397046B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016397046A 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of inflammatory conditions Active AU2016397046B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2016/050635 WO2017153701A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

Publications (2)

Publication Number Publication Date
AU2016397046A1 AU2016397046A1 (en) 2018-09-06
AU2016397046B2 true AU2016397046B2 (en) 2022-05-12

Family

ID=55646778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016397046A Active AU2016397046B2 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

Country Status (9)

Country Link
US (1) US10617674B2 (enExample)
JP (1) JP6741773B2 (enExample)
KR (1) KR20180119597A (enExample)
AU (1) AU2016397046B2 (enExample)
BR (1) BR112018067784A2 (enExample)
CA (1) CA3016368A1 (enExample)
MX (1) MX389563B (enExample)
RU (1) RU2709509C1 (enExample)
WO (1) WO2017153701A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385717B (es) * 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
JP7280627B2 (ja) * 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009973A1 (en) * 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
WO2013139809A1 (en) * 2012-03-20 2013-09-26 Novartis Ag Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
RU2381219C2 (ru) * 2003-06-26 2010-02-10 Новартис Аг ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) * 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
US20090270350A1 (en) * 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009973A1 (en) * 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
WO2013139809A1 (en) * 2012-03-20 2013-09-26 Novartis Ag Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
JP2019507785A (ja) 2019-03-22
MX2018010781A (es) 2018-11-09
RU2709509C1 (ru) 2019-12-18
US10617674B2 (en) 2020-04-14
WO2017153701A1 (en) 2017-09-14
JP6741773B2 (ja) 2020-08-19
MX389563B (es) 2025-03-20
AU2016397046A1 (en) 2018-09-06
US20190091203A1 (en) 2019-03-28
CA3016368A1 (en) 2017-09-14
BR112018067784A2 (pt) 2019-01-15
KR20180119597A (ko) 2018-11-02

Similar Documents

Publication Publication Date Title
US11129810B2 (en) Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
AU2016397046B2 (en) Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
AU2018381874B2 (en) Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
AU2018382895B2 (en) Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
HK40020427B (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention of acute exacerbations of chronic obstructive pulmonary disease
HK40020427A (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention of acute exacerbations of chronic obstructive pulmonary disease
HK40020426B (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
HK40020426A (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)